Affinité Instruments

2025 wasn't a cost reset — it was a clarity reset. We stopped selling and started asking the questions we should have asked earlier.

We tested our message at every level — field conversations, 6 newsletters, 2 application notes, a conference poster. The signal came back consistent across all of it: researchers don't want to master SPR. They want quick, reliable binding data — a simple entry point into the technology and a platform to develop biosensors. The demand is real. Complexity is the only barrier. Remove it, and the market is far larger than we ever sold into.

We assumed the gap was hardware. We were wrong. The instrument was ready — the experience around it wasn't. 15 years of hard-won SPR knowledge lived in our heads, not in the product. We spent 6 months rebuilding the software from scratch. LLM became the unlock: for the first time, we can embed what we know directly into what users experience — no expert required.

We also looked at our own history without flinching. Four commitments going forward: use what you sell · document obsessively · go slow and focused · lead with service. And one deliberate market shift — anchor in biotech, reduce dependence on academia. Service is the fastest path to revenue, and biotech is where it closes.

SPR is where PCR was in 1990. We are kitasizing it.